Dette gælder især data, som bekræfter effekten hos patienter med tumorer med KRAS- vildtypen, hvilket aktuelt understøttes af en retrospektiv analyse.
This means that further evidence on this medicinal product is awaited, in particular data are required to confirm the effect in patients with wild-type KRAS tumours which is currently supported by a retrospective analysis.